Ubamatamab

DB18875InvestigationalProtein Based Therapies

Ubamatamab is under investigation in clinical trial NCT03564340 (Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing...

Mechanism: Pharmacologically active on Mucin-16 and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: Anti-muc16/cd3 bite antibody regn4018 · Bispecific t-cell engager antibody regn4018 · Muc16xcd3 bispecific t-cell engager regn4018
Code names: REGN-4018

Resolves to

Compound

UNII6BUL1G4D60CAS2305629-50-7

Targets

Q8WXI7MUC16

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ubamatamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account